PL364749A1 - Metody leczenia oraz metody badań przesiewowych leku - Google Patents
Metody leczenia oraz metody badań przesiewowych lekuInfo
- Publication number
- PL364749A1 PL364749A1 PL00364749A PL36474900A PL364749A1 PL 364749 A1 PL364749 A1 PL 364749A1 PL 00364749 A PL00364749 A PL 00364749A PL 36474900 A PL36474900 A PL 36474900A PL 364749 A1 PL364749 A1 PL 364749A1
- Authority
- PL
- Poland
- Prior art keywords
- ppar delta
- patient
- treatment
- cardiovascular diseases
- delta inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 101150014691 PPARA gene Proteins 0.000 title 1
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000000497 foam cell Anatomy 0.000 abstract 2
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000011712 cell development Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 230000007505 plaque formation Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9917405.4A GB9917405D0 (en) | 1999-07-23 | 1999-07-23 | Methods of treatment and drug screening methods |
| PCT/EP2000/006986 WO2001007066A2 (en) | 1999-07-23 | 2000-07-19 | Ppar delta inhibitors for the treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL364749A1 true PL364749A1 (pl) | 2004-12-13 |
| PL205747B1 PL205747B1 (pl) | 2010-05-31 |
Family
ID=10857874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL364749A PL205747B1 (pl) | 1999-07-23 | 2000-07-19 | Zastosowanie inhibitora aktywności PPARδ |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1200114B1 (pl) |
| JP (1) | JP2003505058A (pl) |
| KR (1) | KR20020012323A (pl) |
| CN (1) | CN1364087A (pl) |
| AR (1) | AR027832A1 (pl) |
| AT (1) | ATE430577T1 (pl) |
| AU (1) | AU6825900A (pl) |
| BR (1) | BR0012661A (pl) |
| CA (1) | CA2378462A1 (pl) |
| CO (1) | CO5280202A1 (pl) |
| CY (1) | CY1109255T1 (pl) |
| CZ (1) | CZ2002247A3 (pl) |
| DE (1) | DE60042161D1 (pl) |
| DK (1) | DK1200114T3 (pl) |
| ES (1) | ES2326785T3 (pl) |
| GB (1) | GB9917405D0 (pl) |
| HK (1) | HK1046094B (pl) |
| HU (1) | HUP0201966A3 (pl) |
| IL (1) | IL147363A0 (pl) |
| MX (1) | MXPA02000880A (pl) |
| MY (1) | MY140626A (pl) |
| NO (1) | NO20020326L (pl) |
| NZ (1) | NZ573856A (pl) |
| PL (1) | PL205747B1 (pl) |
| PT (1) | PT1200114E (pl) |
| SI (1) | SI1200114T1 (pl) |
| TR (2) | TR200200211T2 (pl) |
| WO (1) | WO2001007066A2 (pl) |
| ZA (1) | ZA200200542B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL153543A0 (en) * | 2000-07-20 | 2003-07-06 | Bristol Myers Squibb Co | PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY |
| WO2002070011A2 (en) * | 2001-02-02 | 2002-09-12 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
| GB0103809D0 (en) | 2001-02-16 | 2001-04-04 | Univ Dundee | Methods |
| US20050171084A1 (en) * | 2002-03-27 | 2005-08-04 | Cairns William J. | Methods of treatment with lxr modulators |
| GB0302446D0 (en) * | 2003-02-03 | 2003-03-05 | Imp College Innovations Ltd | Screening for modulators of fat storage |
| US20070037882A1 (en) * | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
| AU2005289520A1 (en) * | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
| DE102006033394A1 (de) * | 2006-07-13 | 2008-01-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verfahren zum Auffinden von antiatherosklerotischen Substanzen |
| JP5367584B2 (ja) * | 2007-01-08 | 2013-12-11 | ソウル ナショナル ユニバーシティー インダストリー ファンデーション | ペルオキシソーム増殖因子活性化受容体δリガンドチアゾール化合物及びこれを含有する医薬、化粧品及び健康食品組成物 |
| CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CN1234029A (zh) * | 1996-08-27 | 1999-11-03 | 盐野义制药株式会社 | 色烯-3-羚酸衍生物 |
| ATE462433T1 (de) * | 1996-12-11 | 2010-04-15 | Dana Farber Cancer Inst Inc | Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums |
| AU6773598A (en) * | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
| PT1016714E (pt) * | 1997-06-27 | 2003-09-30 | Ono Pharmaceutical Co | Novo adn plasmidico que compreende adn do gene reporter e sua utilizacao |
| CA2295930C (en) * | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
-
1999
- 1999-07-23 GB GBGB9917405.4A patent/GB9917405D0/en not_active Ceased
-
2000
- 2000-07-19 PL PL364749A patent/PL205747B1/pl not_active IP Right Cessation
- 2000-07-19 AT AT00956238T patent/ATE430577T1/de active
- 2000-07-19 DE DE60042161T patent/DE60042161D1/de not_active Expired - Lifetime
- 2000-07-19 ES ES00956238T patent/ES2326785T3/es not_active Expired - Lifetime
- 2000-07-19 DK DK00956238T patent/DK1200114T3/da active
- 2000-07-19 AU AU68259/00A patent/AU6825900A/en not_active Abandoned
- 2000-07-19 SI SI200031033T patent/SI1200114T1/sl unknown
- 2000-07-19 WO PCT/EP2000/006986 patent/WO2001007066A2/en not_active Ceased
- 2000-07-19 EP EP00956238A patent/EP1200114B1/en not_active Expired - Lifetime
- 2000-07-19 IL IL14736300A patent/IL147363A0/xx unknown
- 2000-07-19 PT PT00956238T patent/PT1200114E/pt unknown
- 2000-07-19 BR BR0012661-6A patent/BR0012661A/pt not_active Application Discontinuation
- 2000-07-19 NZ NZ573856A patent/NZ573856A/en unknown
- 2000-07-19 TR TR2002/00211T patent/TR200200211T2/xx unknown
- 2000-07-19 HK HK02107665.7A patent/HK1046094B/en not_active IP Right Cessation
- 2000-07-19 CA CA002378462A patent/CA2378462A1/en not_active Abandoned
- 2000-07-19 KR KR1020027000942A patent/KR20020012323A/ko not_active Ceased
- 2000-07-19 JP JP2001511949A patent/JP2003505058A/ja active Pending
- 2000-07-19 CZ CZ2002247A patent/CZ2002247A3/cs unknown
- 2000-07-19 TR TR2005/01763T patent/TR200501763T1/xx unknown
- 2000-07-19 HU HU0201966A patent/HUP0201966A3/hu not_active Application Discontinuation
- 2000-07-19 CN CN00810779A patent/CN1364087A/zh active Pending
- 2000-07-19 MX MXPA02000880A patent/MXPA02000880A/es unknown
- 2000-07-21 CO CO00054777A patent/CO5280202A1/es not_active Application Discontinuation
- 2000-07-21 AR ARP000103776A patent/AR027832A1/es unknown
- 2000-07-21 MY MYPI20003340A patent/MY140626A/en unknown
-
2002
- 2002-01-22 ZA ZA200200542A patent/ZA200200542B/en unknown
- 2002-01-22 NO NO20020326A patent/NO20020326L/no not_active Application Discontinuation
-
2009
- 2009-07-15 CY CY20091100754T patent/CY1109255T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999046279A3 (en) | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | |
| WO2005072409A3 (en) | Method and apparatus for detecting vascular conditions with a catheter | |
| MEP10508A (en) | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
| IL156122A0 (en) | Geldanamycin derivative and method of treating cancer using same | |
| PL340096A1 (en) | Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein | |
| HK1048250A1 (zh) | 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂 | |
| SE9702860D0 (sv) | New use | |
| CY1109255T1 (el) | Ppar δελτα αναστολεις για την αντιμετωπιση καρδιαγγειακων νοσων | |
| WO2002000210A3 (en) | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease | |
| IL165834A0 (en) | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases | |
| GB9702943D0 (en) | Wound healing | |
| WO2004037208A3 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| AU6539000A (en) | Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue | |
| EP1447090B8 (de) | Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen | |
| AU2003283227A8 (en) | Method and means for the treatment of vascular and cardiac diseases | |
| WO2002024144A3 (en) | Use of transcription factors for treating inflammation and other diseases | |
| IL153426A0 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| CZ223199A3 (cs) | Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí | |
| WO1999043308A3 (en) | Treating pulmonary hypertension through tenascin suppression and elastase inhibition | |
| WO2001041771A3 (de) | Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne | |
| MY118982A (en) | Method of reducing tissue damage associated with ischemia | |
| EP1321146A3 (en) | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | |
| WO2004035030A3 (en) | Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain | |
| CA2306772A1 (en) | Use of c18 to c26 aliphatic alcohols for the manufacture of a medicament in the treatment of hyperproliferative skin disorders | |
| WO2006036804A3 (en) | Methods for the treatment and prevention of diseases of biological conduits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VDSO | Invalidation of derivated patent or utility model |
Ref document number: 387398 Country of ref document: PL Kind code of ref document: A1 |
|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20110719 |